No Data
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Surges 5.3%; Individual Investors Who Own 34% Shares Profited Along With Institutions
H.C. Wainwright Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $72
RAPT Therapeutics: Promising Pipeline and Superior Efficacy of Lead Candidate Ozureprubart
Rapt Therapeutics Participates in a Conference Call With H.C. Wainwright
RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Market Cap Touched US$830m Last Week, Benefiting Both Individual Investors Who Own 34% as Well as Institutions
Rapt Therapeutics Is Maintained at Overweight by JP Morgan